Piramal Pharma Acquires Yapan Bio
Piramal Pharma strengthens its biologics CDMO business, converting Yapan Bio from associate company to subsidiary and expanding vaccine and biologics manufacturing capabilities.
Piramal
Piramal Pharma Solutions Expands CDMO Capabilities at Michigan Facility
Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.
Piramal to Expand US Facility for Sterile Injectables
US contract development and manufacturing organization (CDMO) Piramal Pharma Solutions (PPS), part of India-headquartered Piramal Pharma, plans to invest $80 million for the expansion of its Lexington, Kentucky, facility.
Piramal Expands ADC and API Capacities in the UK
Piramal Pharma Solutions has announced plans to invest a total of £55 million in two expansions at Grangemouth, Scotland, and Morpeth, UK. The Indian CDMO said the projects have been driven by several pipeline products moving to commercial scale, coupled with increased customer demand for antibody-drug conjugates (ADCs) and APIs.
Opportunities in Drug Development and Manufacturing
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
